Developing Novel Therapies for
a Broad Range of Pain Indications

Centrexion Therapeutics recognizes the needs of the those living with chronic pain and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments.

 

Centrexion Therapeutics Pipeline

At Centrexion Therapeutics, we believe that we have one of the industry’s largest pipelines of novel, non-opioid clinical stage product candidates for the treatment of chronic pain. Our product candidates are designed to work on multiple types of chronic pain, including that of neuropathic and inflammatory origin, which are associated with a wide variety of diseases where pain is a co-morbid condition. We believe that our broad therapeutic pipeline of non-opioid chronic pain therapeutics is uniquely positioned to address the limitations of currently-available therapies by providing safe, effective and durable pain treatment solutions, as well as treat chronic pain as the disease itself, rather than as a symptom.

6016

CB2 agonist Oral
Phase 2
Diabetic Peripheral Neuropathic Pain

0066

TrkA inhibitor Intraarticular
Phase 2
Knee Osteoarthritis Pain

3001

NOPr agonist Intrathecal
Phase 2a
Chronic Pain

0290

SSTR4 Agonist Oral
Phase 2b
Diabetic Peripheral Neuropathic Pain